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HLA-B*57
HLA-B*5801Viral mutations at Gag residue 242 and relevant viral polymorphisms were analyzed in a cohort of 42
individuals with primary HIV-1 subtype C infection using single-genome ampliﬁcation/sequencing. In HLA-
B*57/5801-negative subjects infected with 242N escape variant, reversion to Asn appeared at median (IQR)
103 days (97–213 days) post-seroconversion (p/s) and became dominant at 193 days (170–215 days) p/s.
In subjects expressing HLA-B*57/5801 and infected with the wild-type virus, the T242N escape appeared at
203 days (196–231) p/s, reached dominance at 277 days (265–315 days) p/s, and became complete at
323 days (289–373 days) p/s. HLA-B*57/5801-negative subjects infected with 242N escape variant did not
show reduced viral load or increased CD4 count. The study highlights the differential selection of T242N
escape by HLA-B*57 and B*5801 and suggests that the presence of HLA-B*57/5801-mediated immune
pressure is able to control replication of the wild-type virus encoding Thr at Gag residue 242 but fails to
suppress the T242N escape variant.th AIDS Initiative, FXB 402, 651
17 739 8348.
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The HIV-1 Gag protein is one of the most functionally and struc-
turally constrained proteins of HIV-1 and is a robust inducer of po-
tent virus-speciﬁc immune responses. Potential association between
T-cell responses to Gag and better control of viral replication, lower
viral set point, and more favorable disease prognosis (Betts et al.,
2001; Boaz et al., 2002; Edwards et al., 2002; Geldmacher et al., 2007;
Kiepiela et al., 2007; Masemola et al., 2004; Ndongala et al., 2009;
Novitsky et al., 2003, 2006; Ramduth et al., 2005; Rolland et al., 2008;
Serwanga et al., 2009; Zuniga et al., 2006) has led to a wide interest
in HIV-1 Gag as an attractive immunogen for an HIV-1 vaccine design.
The MHC class I HLA alleles can affect the progression of HIV
disease (O'Brien and Nelson, 2004). HIV-infected subjects expressing
HLA-B*57 or -B*5801 have better clinical prognoses than HLA-B*57/
5801-negative individuals (Altfeld et al., 2003; Goulder et al., 1996;
Kaslow et al., 1996; Klein et al., 1998; Migueles et al., 2000), which is
likely due to efﬁcient processing and presentation of viral epitopes tovirus-speciﬁc CD8+ T cells. In fact, the number of Gag escape muta-
tions targeted by HLA-B-restricted CTL responses was associated with
lower viral load in newly infected individuals (Goepfert et al., 2008).
TheHIV-1 subtypeBGag p24 epitope TSTLQEQIGW, known as TW10
at Gag amino acid residues 240 to 249, was found to be one of the three
most targeted CTL epitopes in individuals expressing MHC class I HLA-
B*57 or -B*5801 within the ﬁrst 6 months of infection (Altfeld et al.,
2003). Kawashima et al. (2009) reported a strong correlation between
frequency of escape mutation at Gag position 242 and HLA-B*57/5801
prevalence in the population. The HIV-1 subtype C version of TW10
epitope is TSTLQEQIAW (Los Alamos National Laboratory, 2009). In
chronic HIV-1 infection, 74% of HLA-B*57/5801-positive individuals
exhibit the T242Nmutation (Martinez-Picado et al., 2006). In a series of
in vitro experiments, the T242N mutation was associated with reduced
viral replicative capacity (Martinez-Picado et al., 2006), providing a
justiﬁcation for reversion to the wild-type Thr at Gag residue 242 after
transmission to individuals who do not express HLA-B*57/5801. The
T242N substitution reduces viral ﬁtness (Leslie et al., 2004; Martinez-
Picado et al., 2006). In vitro experiments addressing the ﬁtness cost of
mutation at Gag residue 242 determined the viral relative replication
capacity of T242N escape as 0.86 (Boutwell et al., 2009). It has been
recently shown that HLA-B*57/5801-negative individuals infectedwith
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counts (Chopera et al., 2008).
However, the timing of in vivo Gag mutations including one of
the best-studied HIV-1 epitopes, TW10, has been understudied. The
limitation of cross-sectional studies to address timing of viral muta-
tions is well recognized. For example, if time of infection is unknown
or cannot be estimated, the prospective sampling during chronic HIV
infection has limited ability to address the time the mutation occur in
the course of HIV infection and to compare or synchronize the timing
data between studies. In contrast, studies focusing on primary HIV
infection cohorts have power to analyze timing of mutations, but few
have addressed the evolution of Gag mutations. For example, tracking
viral sequence changes in Gag p24 in ﬁve acutely infected HLA-
B*5703-positive individuals, Crawford et al. (2009) found that T242N
escape occurred at a median of 13 months post-seroconversion (p/s)
ranging from 4 to 18 months. Besides the small sample size, sys-
tematic frequent longitudinal sampling is still a challenge even for
primary HIV infection cohorts.
While it is known that in vivo N242T reversion might be rapid
upon transmission, the time of N242T reverse mutation has been
addressed sporadically within a relatively small number of cases, or
infrequent sampling (Chopera et al., 2008; Crawford et al., 2009;
Kawashima et al., 2009; Leslie et al., 2004; Thobakgale et al., 2009), or
without the context of time of infection/seroconversion (Crawford et
al., 2007). Leslie et al. (2004) reported vertical transmission of HIV-1
from an HLA-B57/5801-positive mother to HLA-B57/5801-negative
children that resulted in N242T reversion from 5 to 9 months after
transmission. In a subject followed longitudinally, the N242T variants
were not seen at day 43 p/s but were detected at day 818 p/s, and
reached complete substitution by day 1541 p/s (Leslie et al., 2004).
Chopera et al. (2008) observed N242T reversions between 6 and
24 months post-infection in ﬁve of six individuals infected with the
242N variant. In nine HLA-B*5703-negative individuals, the reverse
N242Tmutationswere detected at amedian of 23 months p/s ranging
from 7 to 55 months (Crawford et al., 2009). Recently, Thobakgale et
al. (2009) reported two cases of vertical transmission of 242N variant
from HLA-B*5702-positive mother to HLA-B*5702-negative child
followed by reversion to 242T between 773 and 819 days post-
delivery, and from HLA-B*5801-positive mother to HLA-B*5801-
negative child without reversion up to 1363 days post-delivery.
Cumulatively, these studies provide an important step toward better
understanding of the dynamics of viral mutational pathways in HIV
infection. At the same time, the relatively vague time intervals of
observed mutations highlight the importance of addressing the
timing of appearance and ﬁxation of in vivo HIV mutations.
In this study, we focused on the timing patterns of viral mutations
at Gag residue 242 within epitope TW10 and analyzed potential
associations between Gag 242 mutations and viral load in primary
HIV-1 subtype C infection utilizing a cohort of 42 individuals with
estimated time of seroconversion and frequent sampling during
primary infection.
Results
To assess the in vivo dynamics of viral quasispecies in the context
of Gag residue 242, the frequency and timing of Gag mutations were
analyzed longitudinally in the cohort of 42 subjects with estimated
time of seroconversion. Potential associations between frequency of
viral mutations at Gag residue 242 and plasma RNA load or CD4+ T-
cell counts were analyzed in individuals expressing or not expressing
HLA-B*57/5810.
In vivo escape and reversion at Gag residue 242
Changes in amino acid frequency at Gag residue 242were detected
in 12 out of 42 (28.6%) subjects. To evaluate the evolutionary patternsof mutational pathways, the observed frequency of viral quasispecies
at Gag residue 242 were plotted over time with time zero as the
estimated time of seroconversion (Fig. 1). The escape mutation from
Thr to Asnwas detected in ﬁve subjects including two acutely infected
individuals, C-3312 and F-3505, expressing either HLA-B*57 (subject
RA-6343) or B*580101 (four subjects; Fig. 1A). In three of those
subjects, F-3505, PO-5062, and RA-6343, Thr was a single amino acid
in the pool of viral quasispecies present at the time close to
seroconversion, which was conﬁrmed by 2 to 3 sampling time points
before escape occurred. The transmission of a single viral variant in
these subjects was conﬁrmed by analysis of gag diversity and
Hamming distances at the earliest time points, as presented
elsewhere (Novitsky et al., 2009c). The escape from Thr to Asn was
gradual, which was evident from increasing frequencies in the pool of
viral quasispecies over time. In two other subjects expressing HLA-
B*580101, C-3312, and PK-4872, a mixture of both Thr and Asn was
detected at the earliest available time points, day 4 p/s (242T 95% CI:
0.92–1.02) and day 47 p/s (242T 95% CI: 0.37–1.05), respectively, but
Thr was completely substituted by Asn at the next time point in both
subjects (Fig. 1A). The T242N escape was complete (reached 100% in
the pool of viral quasispecies) in all ﬁve subjects. It is likely that the
coexistence of both Thr and Asn in the pool of viral quasispecies upon
transmission to a new host can facilitate escape mutations in indi-
viduals expressing HLA-B*57/5801.
In contrast, ﬁve subjects who did not express HLA-B*57 or B*5801
demonstrated reversion from Asn to Thr or a mix of Thr/Asn (Fig. 1B).
Analysis of multiplicity of HIV-1 infection provided evidence for a
single transmitted viral variant in four of ﬁve subjects, B-2865, OC-
2381, OM-2869, and PA-3390. Although Asn at amino acid position
242 was found in 10 out of 10 sequenced quasispecies in subject PP-
5065 at day 44 p/s, levels of gag diversity and Hamming distances in
this subject argued for transmission of multiple viral variants.
Therefore, we cannot exclude a possibility that minor 242T variant
was present in the pool of transmitted quasispecies in subject PP-5065
below the level of detection by methodology used in the current
study. The gradual nature of the N242T reversion was similar to the
pattern of T242N escape. The opposite patterns of mutations, escape
and reversion, observed in subjects expressing or not expressing HLA-
B*57/5801, respectively, further conﬁrm a remarkably efﬁcient
restriction of the TW10 epitope by MHC class I HLA HLA-B*57 and
B*5801. Interestingly, four of ﬁve HLA-B*57/5801-negative subjects
did not reach complete amino acid substitution during reversion over
the follow-up period, even by day 755 p/s, as seen in subject OC-2381
(Fig. 1B). A transient Ser was observed at day 129 p/s in subject PA-
3390. Two subjects, PA-3390 and PP-5065, expressed HLA-B*5802,
highlighting the inability of this MHC class I HLA molecule to restrict
epitope TW10.
Viral mutation from Asn to Ser at Gag residue 242 that was de-
scribed previously as a transient mutation (Crawford et al., 2007) was
detected in two HLA-B*57/5801-negative subjects, OX-3251 and PD-
3508 (Fig. 1C). These two subjects did not share any class I HLA allele
(Fig. 1C), suggesting that some alternative mechanisms may be in-
volved. Subject PD-3508 had Ala-to-Pro mutation at Gag residue 146
as one of only six Gag mutations occurring from 59 to 428 days p/s,
while subject OX-3251 had as many as 47 mutations across Gag from
58 to 555 days p/s, but none was among the list of polymorphisms
related to mutations at Gag residue 242 (see below).
Gag polymorphisms relevant to mutations at residue 242
Mutations at Gag residue 242 are likely to be affected by other
mutants within or ﬂanking the TW10, ISW9, or KF11 epitopes
(Brumme et al., 2008; Crawford et al., 2007, 2009; Martinez-Picado
et al., 2006; Matthews et al., 2008, 2009). Therefore, subjects with
detectable mutations at Gag residue 242 were analyzed for viral
polymorphisms at Gag residues 146, 147, 163, 165, 243, 247, 248, 250,
Fig. 1. The dynamics of in vivomutations at Gag residue 242 and related polymorphisms in 12 subjects infected with HIV-1 subtype C. Panels A, B, and C outline subject ID, MHC class I
HLA proﬁle, frequency (axis y), and kinetics (axis x) of viral quasispecies in the pool of viral quasispecies at Gag residue 242, and dynamics of related mutations below the
corresponding graph, if any. Time is shown in days from estimated time of seroconversion. Numbers within the graphs outline frequency of closest amino acid at given time point in
the pool of viral quasispecies (the frequency of the second amino acid equals 1 – frequency of the shown amino acid). The related polymorphisms were analyzed at Gag residues 146,
147, 163, 165, 243, 247, 248, 250, and 252. Presence of the related polymorphisms is shown as a stretch of changing amino acids at speciﬁed Gag residue (e.g., L243F delineates
substitution of Leu by Phe at position 243) followed by observed frequency of emerging amino acid residue at speciﬁed time point in relation to the estimated seroconversion (e.g.,
L243F: 0.13292 p/s stands for the 13% frequency of the emerging amino acid, Phe, at day 292 p/s and, given the time scale at the 242-graph, represents a transient polymorphism
observed at a single time point). In case of dynamic changes in the frequency, the observed related polymorphisms are presented as a stretch of amino acid frequencies at the
speciﬁed time point (e.g., “0261 0.50323 0.50447” below “S146A: 0.50323 p/s” delineates changing frequency of Ala at Gag residue 146 from 0 at day 261 p/s to 0.50 at day 323 p/s, and
remaining at frequency 0.50 at day 447 p/s; frequency of “0.50 323 p/s” immediately following “S146A” outlines the highest-frequency ﬁrst time observed at the speciﬁed time point).
Nonconsensus residues without detectable dynamics in the pool of viral quasispecies are outlined at the bottom of graphs A, B, and C (e.g., “147L: 1.04–445 p/s” delineates the presence
of nonconsensus Leu at Gag residue 147 (Iso corresponds to the consensus amino acid at position 147; see panel D) at frequency 100% over the follow-up period from day 4 p/s to day
445 p/s). A: Five HLA-B*57/5801-positive subjects with T242N escape mutations. B: Five HLA-B*57/5801-negative subjects with N242T reverse mutations. C: Two HLA-B*57/5801-
negative subjects with N242S mutations. D: List of amino acid residues related to mutations at Gag residue 242 (amino acid positions are shaded by gray bar) and frequency of
corresponding amino acid residues among HIV-1 subtype C (n=1871; for details, see Extended HIV-1 subtype C consensus sequence in the Materials and methods section).
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Fig. 1 (continued).
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consensus at these positions are outlined in Fig. 1D. Polymorphisms at
speciﬁed Gag residues were detected in 10 of 12 analyzed cases. The
Ser-to-Gly at residue 252 accompanied T242N escape in three of ﬁve
cases (Fig. 1A). In addition, the Ser-to-Asn and Ser-to-His substitu-
tions at position 252 were detected in one subjects with T242N
escape, PO-5062 (Fig. 1A), and one subject with N242T reversion, PP-
5065 (Fig. 1B), respectively. The heterogeneity of viral polymorph-
isms at Gag residue 252was evident by a complete S252G substitution
in subject F-3505 and transient appearance of Gly or Asn in three
other T242N escape cases (Fig. 1A) and transient appearance of His in
case of N242T reversion (Fig. 1B). The diverse polymorphisms at Gag
residue 146 were observed in 7 of 12 subjects accompanying four of
ﬁve N242T reversions (Fig. 1B), two T242N escape (Fig. 1A), and one
N242S mutation (Fig. 1C). A complete A146P mutation was detected
in two subjects, RA-6343 (Fig. 1A) and PD-3508 (Fig. 1C). Other
polymorphisms at Gag residue 146 were represented by the A146P
escape (subjects OC-2381 and PP-5065; Fig. 1B) or P146A reversion
(subjects B-2865 and PA-3390; Fig. 1B) or toggling between Pro and
Ser (subjects F-3505, Fig. 1A; and B-2865 and OM-2869, Fig. 1B).
Other observed polymorphisms at positions relevant to mutations at
Gag residue 242 included transient escapemutations at I147L (subject
RA-6343), L243F (C-3312), I247V (RA-6343), A248G (PP-5065), and
M250I (PO-5062); dominant escape at M250T (OM-2869); and
transient reversions at N165S and V247I (both in PP-5065). Except
described polymorphisms related to mutations at Gag residue 242,
nonconsensus amino acid substitutions were detected in 9 of 12
subjects (Figs. 1A, B, and C). The 147L, 163G, 165N, and 252Gwere the
most common nonchanging substitutions accompanying viral muta-
tions at Gag residue 242. Two subjects with N242S mutations have
similar proﬁle of 147L and 252G (Fig. 1C), suggesting that the
background of 147L and 252Gmight provide replicative advantage for
the 242S variant as compared with the 242T wild-type virus.
Timing of in vivo mutations at Gag residue 242
Timing constraints of the in vivo mutations at Gag residue 242
were assessed separately in subjects expressing or not expressing
MHC class I HLA-B*57/5801 (Fig. 2). Appearance, dominance, andcompleteness occurred within relatively tight time intervals among
subjects. Thus, in the three HLA-B*57/5801-positive subjects infected
with thewild-type Thr at Gag residue 242, the T242N escape appeared
at 193, 203, and 240 days p/s, reached dominance at 261, 277, and
328 days p/s, and became complete at 277, 323, and 389 days p/s
(Fig. 2A). In ﬁve HLA-B*57/5801-negative subjects infected with
242N variant, the 242T reverse mutation appeared at median (IQR)
103 days (97–213 days) p/s, became dominant at 193 days (170–
215 days) p/s, but reached completeness only in one of ﬁve subjects,
PP-5065, over the follow-up period (Fig. 2A). While the appearance
time did not differ between reverse (n=5) and escape mutations
(n=3; P=0.39), the time to reach dominance at Gag residue 242
appeared to be shorter for reverse mutations (P=0.057). Transmis-
sion of 242TN mix to subjects expressing HLA-B*57/5801 resulted in
fast 242N escape that reached completeness at 95 days p/s in subject
C-3312 and at 108 days p/s in subject PK-4872, although a rapid
escape before the time of sampling in the last case cannot be ruled out.
No evidence for transmission of 242TN mix to HLA-B*57/5801-
negative subjects was found, but we cannot exclude this in subject
OM-2869 due to late sampling.Viral RNA load in HLA-B*57/5801-negative subjects
Subjects who do not express HLA-B*57/5801 were reported to
have lower viral load upon transmission of 242N variant (Chopera et
al., 2008) due to the apparent lower ﬁtness of escape 242N variant.
We tested whether viral RNA load differed between HLA-B*57/5801-
negative subjects with (n=7; Figs. 1B and C) and without (n=26
who did not express HLA-B*57/5801 and did not have mutations at
Gag residue 242 in the study cohort) transmitted Asn at Gag residue
242 over time (Fig. 3A). We found no evidence for reduced viral load
in HLA-B*57/5801-negative subjects infected with 242N at any of the
analyzed time intervals up to 500 days p/s (Fig. 3A). Next, we tested
whether HLA-B*57/5801-negative subjects infected viral variant
encoding Asn at Gag residue 242 have increased CD4+ T-cell count
(Fig. 3B). Similar to viral load, no differences were detected in the
levels of CD4+ T-cell count between groups of HLA-B*57/5801-
negative subjects with and without transmitted Asn.
Fig. 2. Timing of in vivo mutations at Gag residue 242. The time scale shows days from
estimated seroconversion. In the box plots, the boundary of the box closer to zero
indicates the 25th percentile, a solid line within the box marks the median value, and
the boundary of the box farther from zero indicates the 75th percentile. A: Timing of
escape mutation T242N in HLA-B*57/5801-positive subjects infected with the wild-
type 242T. B: Timing of reverse mutation N242T in HLA-B*57/5801-negative subjects.
Time of completeness for reverse mutation was not calculated because N242T reached
completeness in only one of ﬁve cases.
41V. Novitsky et al. / Virology 403 (2010) 37–46Viral RNA load in HLA-B*57/5801-positive subjects
Not all subjects expressing HLA-B*57/5801 demonstrate Gag
T242N escape mutation in primary HIV-1 subtype C infection. Four
out of nine HLA-B*57/5801-positive subjects in this study maintained
wild-type Thr at Gag residue 242 without evidence for escape to Asn
over the follow-up period.We tested whether viral RNA load differs in
HLA-B*57/5801-positive subjects infected with the wild-type virus
with and without T242N escape mutation in the primary HIV-1
subtype C infection. Subjects without the detectable T242N escape
mutation maintained signiﬁcantly lower viral load than subjects with
T242N escape up to 500 days p/s (Fig. 4A). Three out of four HLA-
B*57/5801-positive individuals with wild-type 242T expressed HLA-
B*5703 or -B*5702, while four out of ﬁve HLA-B*57/5801-positive
individuals with 242N escape expressed HLA-B*5801. Analysis of the
CD4+ T-cell counts between subjects with and without T242N
mutation revealed a trend toward higher CD4 count in HLA-B*57/
5801-positive subjects without T242N escapemutation at three out of
four time intervals (Fig. 4B).
Discussion
This study addressed patterns and timing of the in vivo mutations
at the key amino acid residue 242 within the Gag epitope TW10 in
primary HIV-1 subtype C infection. Four major ﬁndings prompt
discussion. First, the dynamics of viral mutations at Gag residue 242
are predictable in most cases based on the proﬁle of transmitted virus
and expression (or no expression) of MHC class I HLA-B*57/5801 by
the host. Second, if the mutation occurs, the time of viral mutations at
Gag residue 242 might be predicted. Third, HLA-B*57/5801-negativesubjects infected with 242N virus did not have lower viral RNA load or
higher CD4+ T-cell counts when compared with HLA-B*57/5801-
negative subjects infected with the wild-type virus over the ﬁrst year
of HIV-1 subtype C infection, and therefore, our data do not support
the previous report by Chopera et al. (2008). Fourth, we found that
HLA-B*57/5801-positive subjects who maintain the wild-type Thr at
Gag residue 242 without escape to Asn during primary HIV-1 subtype
C infection have signiﬁcantly lower viral RNA load.
The dissecting of viral quasispecies sampled frequently soon after
seroconversion revealed early dynamics of the in vivo proﬁle of viral
mutations at Gag residue 242 in primary HIV-1 subtype C infection.
Consistent with the previous studies (Brumme et al., 2008; Chopera et
al., 2008; Crawford et al., 2007, 2009; Leslie et al., 2004; Martinez-
Picado et al., 2006; Matthews et al., 2008, 2009), expressing or not
expressing HLA-B*57/5801 by an HIV-infected host is predictive of
the direction of mutation, escape or reversion, at Gag residue 242. An
escape from Thr to Asn was seen in HLA-B*57/5801-positive subjects,
while reversion from Asn to Thr was observed in HLA-B*57/5801-
negative individuals. Two HLA-B*57/5801-negative subjects in this
study demonstrated mutation from Asn to Ser, raising the question
why no reversion to Thr occurred. In both subjects, Asn encoded by
AAC was substituted by Ser encoded by AGC (transition), while in
subjects reverting from Asn to Thr, there was a substitution from AAC
to ACC (transversion) on the background of nonconsensus 147L and
252G. Although transition is more likely than transversion, the overall
frequency of Asn-to-Thr at Gag residue 242 is higher than frequency
of Asn-to-Ser, which warrants further study addressing the mecha-
nistic reason for these substitutions and potential compensatory role
of the 147L and 252G background for N242S mutation.
In the case of transmission of a single viral variant, time of T242N
escape was between 203 and 323 days p/s, while N242T reversion
occurred between 103 and 193 days p/s. The reversemutations at Gag
residue 242 reached a state of dominance earlier than escape muta-
tions (P=0.009). However, in contrast to escape mutations, the
reverse mutations at Gag residue 242 did not reach complete amino
acid substitution in four of ﬁve subjects over the follow-up period,
which can be attributable to a relatively short follow-up period in
some cases with N242T reversion.
Our data suggest differential timing of T242N escape mutation in
HLA-B*57/5801-positive subjects depending on the proﬁle of trans-
mitted viral quasispecies. We found that it matters whether trans-
mitted virus includes only a wild-type Thr at Gag residue 242 or a mix
of both Thr and Asn. Transmission of the wild-type Thr led to the
appearance of T242N variants around 203 days p/s that advanced to
compete T242N substitution by day 323 p/s. In contrast, transmission
of 242TN mix resulted in much faster T242N escape that reached
completeness by day 115 p/s. Together with the timing patterns of
viral mutations in HLA-B*57/5801-negative subjects, this ﬁnding
provides important insight for modeling viral evolution on a popu-
lation level and generates a hypothesis that predicts increase of the
242N and 242TN mix in the fraction of transmitted HIV-1 subtype C
viruses in the population with substantial proportion of HLA-B*57/
5801 individuals over time.
We found no difference between levels of viral RNA load or CD4
counts in HLA-B*57/5801-negative subjects infected with 242N
escape variant or with the wild-type virus. This is in contrast to the
recent report by Chopera et al. (2008), which is likely due to some
methodological differences and confounding biases in both studies, as
illustrated below. Chopera et al. (2008) analyzed nine cases with
transmitted A146X (X=P or S), and six of those also showed T242N.
In our study, no cases of transmitted A146X without T242N were
observed, and the heterogeneous patterns of mutations at Gag residue
146 included Ser-to-Ala, Ser-to-Pro, Pro-to-Ala, Pro-to-Ser, Ala-to-Pro,
or no mutation (Fig. 1). It is also possible that early advantage for the
host due to low ﬁtness of transmitted 242N variant may result in low
viral load later on in the course of disease, and if so, our study was not
Fig. 3. Median viral RNA load and CD4+ T-cell counts in MHC class I HLA-B*57/5801-negative subjects are compared between groups with and without transmitted Asn at Gag
residue 242. The upper error represents the 75th percentile. Comparisons between groups were based on Mann–Whitney rank-sum test. Measurements originated during the ﬁrst
50 days p/s were excluded from analysis. A: Plasma viral RNA load over four time intervals: 50–200, 201–300, 301–400, and 401–500 days p/s. B: CD4+ T-cell count over four time
intervals: 50–200, 201–300, 301–400, and 401–500 days p/s.
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limitation of small sample size, further larger studies with longer
follow-up periods are needed to resolve whether and when
transmitted 242N is associated with lower viral RNA load in HLA-
B*57/5801-negative subjects, if any.
HLA-B*57/5801-positive subjects maintaining the wild-type Thr
at Gag residue 242 had signiﬁcantly lower viral RNA load than
subjects with T242N escape. This ﬁnding suggests that the HLA-B*57/
5801-mediated immune pressure is able to control replication of the
wild-type virus encoding Thr at Gag position 242 but cannot suppress
viral replication of the T242N escape variant. Although the 242N viral
variant has a lower ﬁtness in the in vitro assay, its replication capacity
is higher than 242T in the presence of the in vivo immune pressure.
Most of the individuals expressing HLA-B*57 maintained wild-type
virus encoding Thr at Gag residue 242, while most of the individualsexpressing HLA-B*5801 developed T242N escape. This ﬁnding sup-
ports the notion that selection of HIV-1 escape mutants within TW10
epitope by subjects expressing HLA-B*57 and HLA-B*5801 differs with
more frequent selection of T242N escape by individuals expressing
HLA-B*5801 and can explain the observed lower HIV RNA load in
subjects without T242N escape mutation.
Conclusions
The study analyzed the dynamics of in vivo mutations at Gag
residue 242 and related polymorphisms during primary HIV-1
subtype C infection and demonstrated predictive directions and
timing constraints of reverse, N242T, and escape, T242N, mutations
based on the host's MHC class I HLA-B proﬁle and transmitted viral
variant(s). No difference in viral load or CD4 counts was found
Fig. 4. Median viral load and CD4+ T cells in MHC class I HLA-B*57/5801-positive subjects with and without mutations at Gag residue 242. The upper error represents the 75th
percentile. P values were calculated using a Mann–Whitney rank-sum test. Ninety-ﬁve percent conﬁdence intervals on shift parameter were based on inversions of the Mann–
Whitney rank-sum tests (shown below the corresponding P value for each time interval). Positive value of a shift parameter indicates that the values are greater in the group with
mutations at Gag residue 242 than the group without. Measurements originated during the ﬁrst 50 days p/s were excluded from analysis. A: Plasma viral RNA load over four time
intervals in relation to the estimated time of seroconversion: 50–200, 201–300, 301–400, and 401–500 days p/s. B: CD4+ T-cell count over four time intervals in relation to the
estimated time of seroconversion: 50–200, 201–300, 301–400, and 401–500 days p/s.
43V. Novitsky et al. / Virology 403 (2010) 37–46between HLA-B*57/5801-negative subjects infected with the wild-
type virus encoding Thr and the mutant virus encoding Asn at Gag
residue 242. Lack of the T242N escape in HLA-B*57/5801-positive
subjects infected with the wild-type virus was associated with better
control of viral replication during the early phase of HIV-1 subtype C
infection.
Materials and methods
Study subjects
A detailed characterization of the primary HIV-1C infection cohort
from Botswana is provided elsewhere (Novitsky et al., 2008, 2009a,b,
c,d). Brieﬂy, 8 acutely and 34 recently infected subjects withestimated time of seroconversion were enrolled and followed up
prospectively for 500+ days thereafter. For acutely infected subjects,
the time of seroconversion was estimated as the midpoint between
the last seronegative test and the ﬁrst seropositive test (within a week
in most cases). For recently infected subjects, the time of serocon-
version was estimated by the stage assignment of Fiebig et al. (2003)
as described elsewhere (Novitsky et al., 2009b). For time 0, we have
chosen to use the estimated time of seroconversion rather the es-
timated time of HIV infection because frequent sampling in this study
allows reliable measurement of the time of seroconversion based on a
series of laboratory tests, which can be more accurate than estimation
of the time of HIV infection. For comparison with other studies, the
timing numbers in this study can be adjusted by adding 14 to 21 days
and will correspond to the estimated time of infection. The cohort
44 V. Novitsky et al. / Virology 403 (2010) 37–46included 9 males and 33 females with median age of 27 years (IQR
25–32, range 20–56) at enrollment. All subjects in the study were
Botswana nationals, and all infectionswere HIV-1 subtype C (Novitsky
et al., 2009a,d). Viral load and CD4+ T-cell counts were assessed
prospectively during follow-up (Novitsky et al., 2008, 2009a,d).
Viral sequences
Both viral RNA from plasma and cell-associated proviral DNAwere
used for ampliﬁcation of viral sequences. The synthesized cDNA and
proviral DNA templates were subjects for single-genome ampliﬁca-
tion by limiting dilutions (Liu et al., 1996; Palmer et al., 2005) with
some modiﬁcations. Primers F2NST (Carr et al., 1999) (5′-GCG GAG
GCT AGA AGG AGAGAG ATG G) and 1448L (5′-AGG GGT CGC TGC CAA
AGA GTG ATT) were used in the ﬁrst-round PCR. Primers gag-5U (5′-
GTG CGA GAG CGT CAA TAT TAA GAG) and 1445L (5′-GGT CGC TGC
CAA AGA GTG ATT) were used in the second-round PCR. Amplicons
were puriﬁed by Exo-SAP (Dugan et al., 2002) and were sequenced
directly at both strands on the ABI 3730 DNA Analyzer using BigDye
Technology. HYPERMUT v.2.0 (Rose and Korber, 2000) was used to
identify and remove hypermutated sequences from analysis. The
median analyzed viral quasispecies in Gag (IQR) was 58.5 (42.0–73.0)
per subject and 11.1 (8.8–13.6) viral sequences per time point per
subject. Details on RNA and DNA sequences used in the study and
their accession numbers are presented elsewhere (Novitsky et al.,
2009c). The frequencies of translated amino acid sequences were
analyzed using MargFreq (Ray, 2008) per time point per subject. The
frequency of each amino acid residue was expressed as a fraction of 1
in the pool of viral quasispecies at a given time point. Evolution of
amino acid frequencies was plotted over time in relation to the
estimated time of seroconversion as time 0.
Multiplicity of transmitted viruses
This was tested by using the methodology described by Keele et al.
(2008) and reported elsewhere (Novitsky et al., 2009c). In summary,
maximum achievable gag diversity of more than 1% and maximum
achievable number of differences (Hamming distances) of 14 or more
were used as a signature for transmission of multiple viral variants for
analysis of gag quasispecies sequences within the ﬁrst 100 days p/s. In
this study, a total of 30 out of 42 subjects (71%) were infected with
single or closely related viral variants, while transmission of multiple
viral variants was evident in 12 individuals (29%).
Extended HIV-1 subtype C consensus sequence
The analyzed amino acid frequency at studied Gag residues was
compared with the extended HIV-1 subtype C consensus that was
generated as described elsewhere (Novitsky et al., 2002). A total of 1871
HIV-1 subtype C gag sequences with a length of at least 500 nt were
retrieved from the LosAlamosHIVDatabase at http://www.hiv.lanl.gov
(access date September 17, 2009). The set was composed of sequences
from Bangladesh (n=13), Botswana (n=198), Ethiopia (n=39),
France (n=26), India (n=67), Israel (n=22), Kenya (n=16), Malawi
(n=218), Saudi Arabia (n=20), South Africa (n=783), Tanzania
(n=21), United Kingdom (n=23), and Zambia (n=344); fewer than
10 sequences per country from Argentina (n=2), Australia (n=5),
Brazil (n=7), Canada (n=7), Democratic Republic of Congo (7),
Cameroon (1), China (2), Djibouti (1), Denmark (2), Spain (n=6),
Gabon (n=2), Georgia (n=1), Nigeria (n=2), Russia (n=1), Rwanda
(n=2), Senegal (n=8), Somalia (n=2), Uganda (n=3), USA (n=3),
Uruguay (n=1), Yemen (n=1), and Zimbabwe (n=6); and 1 se-
quencewith unknown origin. Frequencies of amino acids at each codon
were expressed as percentages, and the low threshold of detection
was 0.5%.MHC class I HLA typing
High-resolution HLA typing was performed using AlleleSEQR HLA
Sequencing-Based Typing kit (Celera, Alameda, CA) according to the
manufacturer's instructions. Assignment of HLA alleles was imple-
mented by Assign SBT ver. 3.5.1.42 (Conexio Genomics, Applecross,
Australia). Polymorphisms outside the targeted exons that could not
resolve heterozygote combinations are presented as HLA allele
variants in brackets or as two-digit HLA typing results. Related to
the study analyses, 9 of 42 individuals expressed HLA-B*57/5801: 1
B*5702, 3 B*5703, and 5 B*5801.
Statistical analysis
Timing data were summarized with medians (interquartile range
for 25% and 75%). Comparisons of continuous outcomes between two
groups were based on Mann–Whitney rank-sum tests. Ninety-ﬁve
percent conﬁdence intervals on shift parameter were based on
inversions of the Mann–Whitney rank-sum tests. In analyses of
plasma RNA load, measurements originated during the ﬁrst 50 days
p/s were excluded from analysis due to the potential effect of the viral
load peak. Comparisons between groups were performed for time
intervals 50–200, 201–300, 301–400, and 401–500 days p/s comput-
ed as mean values for each subject within the analyzed time intervals.
All reported P values were 2-sided and not adjusted for multiple
testing. Conﬁdence intervals for shift parameter were obtained using
R, version 2.10.1 (The R Project for Statistical Computing, Vienna,
Austria). All other statistical analyses were implemented using
SigmaStat v.3.5. Plots were generated by SigmaPlot v.10 and reﬁned
in Adobe Illustrator CS4.
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